CTRI/2020/04/024949
Recruiting
Phase 2
EFFICACY OF ORAL NICLOSAMIDE IN TREATMENT OF MILD AND VERY MILD COVID-19 CASES: AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL - EONIC-COVID
ady Hardinge Medical College0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B338- Other specified viral diseases
- Sponsor
- ady Hardinge Medical College
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients (\>\=18years) suffering from mild or very mild Covid\-19 (8\). A positive throat swab for nCoV\-2019 (by real time PCR) obtained from a patient suspected to be Covid\-19 or from a contact (or HCW) of Covid\-19 patient will be considered to be a Covid\-19 case, irrespective of the presence of symptoms. Mild disease will be defined as respiratory rate between 12\-18/minute and SpO2 \>\= 95% in room air and no clinico\-radiological (normal chest X\-ray) signs of pneumonia.
Exclusion Criteria
- •Patients with renal or hepatic dysfunction (Serum creatinine \> 1\.5 mg/dL and serum transaminase levels \>120 U/L)
- •Patients with clinical heart failure/known CAD
- •Known cases of neoplasms or immunodeficiency syndromes
- •Patients who are on chemotherapy, immunosuppressive agents, steroids or antiviral agents, or have received in the preceding 4 weeks
- •Pregnant and lactating patients
- •Uncooperative patients (in the opinion of the investigator, if it is difficult to ensure patient cooperation during the study)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Niclosamide for Mild to Moderate COVID-19COVID-19NCT04399356Tufts Medical Center73
Active, not recruiting
Phase 1
Efficacy of thalidomide in the treatment of heavy and frequent nose bleeding in patients affected by hereditary hemorrhagic telangiectasiaSevere recurrent epistaxis in hereditary hemorrhagic telangiectasiaMedDRA version: 14.1Level: LLTClassification code 10038554Term: Rendu-Osler-Weber syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2011-004096-36-ITOSPEDALE POLICLINICO S. MATTEO31
Completed
Phase 4
Safety and efficacy of glinide for the treatment of type 2 diabetic patientstype 2 diabetesJPRN-UMIN000003840Keio University School of Medicine Department of Medicine Division of Nephrology, Endocrinology and Metabolism30
Completed
Not Applicable
Safety and efficacy of lenalidomide for patients with relapsed or refractory adult T cell leukemia/lymphoma post allogeneic hematopoietic stem cell transplantation, multi-institutional prospective observational trialAdult T-cell leukemia-lymphomaJPRN-UMIN000029635Kagoshima University33
Recruiting
Phase 2
Clinical trial of the effectiveness of oral clonidine on pain severity and morphine requirement in patients with orthopedic fracturesIRCT20220822055774N1Kerman University of Medical Sciences64